Tumor microenvironment signaling and therapeutics in cancer progression

A Goenka, F Khan, B Verma, P Sinha… - Cancer …, 2023 - Wiley Online Library
Tumor development and metastasis are facilitated by the complex interactions between
cancer cells and their microenvironment, which comprises stromal cells and extracellular …

Peptides as multifunctional players in cancer therapy

SMP Vadevoo, S Gurung, HS Lee… - … & Molecular Medicine, 2023 - nature.com
Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely,
peptides demonstrate higher efficiency in tissue penetration and cell internalization than …

[HTML][HTML] Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Y Moon, MK Shim, J Choi, S Yang, J Kim, WS Yun… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with
chemotherapeutic drugs has provided significant clinical advances. However, such …

Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy

Y Lin, M Yan, Z Bai, Y Xie, L Ren, J Wei, D Zhu… - Journal of …, 2022 - Springer
Background Effective therapeutics to stop or reverse liver fibrosis have not emerged,
because these potential agents cannot specifically target activated hepatic stellate cells …

An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy

XJ Hu, NY Zhang, DY Hou, ZJ Wang… - Advanced …, 2023 - Wiley Online Library
Anti‐PD‐L1 monoclonal antibody has achieved substantial success in tumor
immunotherapy by T‐cells activation. However, the excessive accumulation of extracellular …

[HTML][HTML] Natural peptides for immunological regulation in cancer therapy: mechanism, facts and perspectives

Y Zhang, C Liu, C Wu, L Song - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Cancer incidence and mortality rates are increasing annually. Treatment with surgery,
chemotherapy and radiation therapy (RT) is unsatisfactory because many patients have …

[HTML][HTML] NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma

F Lu, Y Zhao, Y Pang, M Ji, Y Sun, H Wang, J Zou… - Cancer letters, 2021 - Elsevier
The NLRP3 inflammasome plays a pro-tumorigenic role in various malignancies. However,
its potential role in lymphomagenesis remains unclear. In this study, we identified an …

Bioactive peptide nanodrugs based on supramolecular assembly for boosting immunogenic cell death‐induced cancer immunotherapy

Y Liu, R Chang, R Xing, X Yan - Small Methods, 2023 - Wiley Online Library
Immunogenic cell death (ICD)‐induced immunotherapy holds promise for complete
elimination and long‐term protective immune responses against cancer by combining direct …

[HTML][HTML] Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives

H Aria, M Rezaei - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Abstract Immunogenic Cell Death (ICD) is a type of cell death that kills tumor cells by
stimulating the adaptive immune response against other tumor cells. ICD depends on the …

Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer

Y Wang, Y Chen, DK Ji, Y Huang, W Huang… - Journal of …, 2024 - Springer
Background The combination of programmed cell death ligand-1 (PD-L1) immune
checkpoint blockade (ICB) and immunogenic cell death (ICD)-inducing chemotherapy has …